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the multiplier effect. This novel approach highlighted the unique characteristics 
of Alzheimer’s disease with particular focus on the additional costs and societal 
impact stemming from caring for a patient with Alzheimer’s. Future cost effective-
ness studies need to consider these additional impacts when quantifying their 
results and potential benefit to the health care system. Approaches to modelling 
long term disease impact must therefore be expanded to consider the wide reaching 
societal impact of Alzheimer’s disease to the direct health care costs.
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From 2006-2011: AN ANAlysIs oF A lArge ADmINIsTrATIve clAIms 
DATAbAse
Velez F.F.1, Menzin J.2, Munsell M.2, Frean M.2
1Sunovion Pharmaceuticals Inc., Marlborough, MA, USA, 2Boston Health Economics, Inc., 
Waltham, MA, USA
Objectives: To evaluate patterns of adjunctive therapy with anti-epileptic drugs 
(AED) and AED-specific pharmacy costs among patients with epilepsy over a six-
year time period (2006-2011). MethOds: Study patients were identified from the 
2006-2011 PharMetrics Plus Database. Separate patient cohorts were created for each 
year of analysis. Patients ≥ 18 years of age with ≥ 2 claims for epilepsy (ICD-9-CM 
345.XX) who were continuously eligible for the entire calendar year were selected. 
Demographic characteristics, proportion of patients with adjunctive AED therapy 
(defined as a ≥ 60 day overlap in supply for two different AEDs) and AED phar-
macy costs were evaluated for each calendar year. Overall adjunctive AED therapy 
utilization was further stratified by AED generic/brand status using the following 
categories: adjunctive therapy with two generic AEDs, two branded AEDs, or one 
generic and one branded AED. AEDs were identified and categorized based on NDC 
codes indicative of a generic/branded therapy for each year. Results: Patients 
meeting cohort selection criteria varied for each year of analysis, ranging from 
28,013 to 61,444 (mean age 44.6-46.3 years). The proportion of patients on adjunc-
tive AED therapy stayed relatively constant over the analysis period, increasing only 
slightly over time (2006: 21.2%, 2007: 24.1%, 2008: 23.9%, 2009: 23.9%, 2010: 24.6%, 
2011: 24.7%). Adjunctive generic AED therapy utilization approximately doubled 
over the analysis period (2006: 11.5%, 2011: 21.7%), while branded therapy decreased 
5-fold (2006: 3.1%, 2011: 0.6%) and generic/branded decreased by > 50% (2006: 11.1%, 
2011: 4.9%) adjunctive AED therapy decreased (all P< 0.01). Over the six-year analysis 
period, mean AED pharmacy costs among patients with epilepsy on any adjunctive 
AED therapy decreased by 7.6% (2006: $4,090, 2011: $3,778; P< 0.01). cOnclusiOns: 
In this study, a doubling in the utilization of generic drugs over a six-year period 
was associated with a 7.6% decrease in pharmacy cost.
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Objectives: Because of the risk of progressive multifocal leukoencephalopathy 
(PML), natalizumab is generally recommended as second-line treatment for relaps-
ing-remitting multiple sclerosis (RRMS) patients. For those negative for anti-JC virus 
antibodies, the natalizumab associated risk of PML is low. The objective was to 
estimate the cost-effectiveness of first-line natalizumab versus second-line natali-
zumab treatment (i.e., initiate glatiramer acetate (GA) then switch to natalizumab) 
for RRMS patients negative for anti-JC virus antibodies. MethOds: We used a cohort 
simulation model to estimate the 20-year costs and outcomes of first- and second-
line natalizumab treatment. Model inputs included published natural history pro-
gressions of the Expanded Disability Status Scale (EDSS), treatment effects from 
randomized controlled trials on disease progression and relapse rates, risk of PML, 
and utilities. We used the PharMetrics Plus claims database for total costs, switching 
and discontinuation rates and their associated costs (i.e., first-line treatment with 
GA then switch or discontinue). Outputs for the average patient, discounted at 3% 
per annum, were quality-adjusted life years (QALYs), costs in 2012 US dollars, and 
incremental cost-effectiveness ratios (ICERs). Results: Compared to natalizumab 
as second-line treatment after switching from GA, first-line natalizumab treatment 
was associated with 0.40 incremental QALYs gained, $36,779 more in 20-year costs 
for an ICER of $91,510 per QALY. Compared to first-line GA treatment without switch-
ing, first-line treatment with natalizumab was associated with an ICER of $95,764 
per QALY (likelihood = 0.56 that first-line natalizumab treatment was cost-effective 
at a willingness-to-pay of $100,000 per QALY). First-line natalizumab treatment 
dominated second-line natalizumab treatment when compared to GA treatment 
without switching through principles of extended dominance. cOnclusiOns: 
Treating JC virus negative RRMS patients with natalizumab as a first-line treatment 
provided better value compared to natalizumab use as a second-line agent. More 
aggressive treatment with natalizumab should be considered for RRMS patients 
who are negative for anti-JC virus antibodies.
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Objectives: To compare the cost-effectiveness of fingolimod, teriflunomide, dime-
thyl fumarate and IM IFN β -1a as first-line therapies in treatment of patients with 
Relapsing-Remitting Multiple Sclerosis (RRMS). MethOds: A Markov model was 
developed to simulate the disease progression and to evaluate the cost-effectiveness 
of disease-modifying drugs from a US societal perspective. The time horizon in base 
AD shows a potential budget impact of approximately Brz3,9 million (US$1,8 million) 
for 5 consecutive years. cOnclusiOns: The use of Souvenaid®, a new approach 
in the management of mild AD, can benefit approximately 100.000 patients with 
AD in 5 years and it is estimated to have a relatively small budget impact to SUS, 
since the projections of cost of disease for the same period are Brz154 million and 
potential budget impact of approximately Brz3,9 million.
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Objectives: Parkinson´s disease is a neurodegenerative disorder with an estimated 
incidence of 40-50 cases per 100,00 habitants per year. In this paper, We set out to 
estimate the direct medical costs of Parkinson´s disease. In addition, direct medical 
costs according to age, gender, socio-economic level, severity and educational attain-
ment were evaluated. MethOds: A partial economic evaluation was performed in 
order to analyse the direct medical costs related to Parkinson´s disease. The analysis 
took the perspective of the National Institute of Neurology and Neurosurgery (INNN) 
for the first semester of 2013, including outpatient clinic visits, medications, medi-
cal procedures and laboratory tests, these costs were provided from the INNN´s 
financial managment. A mexican retrospective study of patients having Parkinson´s 
disease from the INNN provided information on severity, baseline characteristics 
and socio-demographic characteristics. Results: Mean first semester direct medi-
cal costs per patient on Parkinson´s disease were US$2 366 in 2013. When analyz-
ing cost distribution, no differences were found in the direct medical costs for 
the modality groups. In severity and gender, costs hadn´t statistical significance 
(p-value> .05). On the other hand, costs by grouped age, grouped socio-economic 
level and educational attainment were statistically different (p-value< .001). Finally, 
in the generalized linear model analysis, direct medical costs were only predicted by 
grouped socio-economic level; age, gender, severity or years of schooling weren´t sta-
tistically sgnificance in the model. cOnclusiOns: The first semester direct medical 
costs per patient on Parkinson´s disease in this study were US$2 366 in 2013. Total 
direct medical costs by grouped age and educational attainment were statistically 
different for patients having Parkinson´s disease. In a multivariate analysis, only 
socio-economic level predicted a higher direct medical cost.
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Objectives: To review studies that investigated the direct and indirect costs of care 
for Parkinson’s disease (PD) in China. MethOds: A structured literature review 
on published articles in both English and Mandarin languages was conducted. 
Literature search was conducted using PubMed, Cochrane, WAN FANG, and VIP 
databases. Articles published between 2000 and 2013 were selected. The inclusion 
criteria included studies on Chinese population based in China only and studies that 
reported direct or indirect cost of PD treatment, management as well as economic 
burden of PD. Four reviewers (two for each language) independently selected and 
reviewed the articles. Subjective quality assessment of the selected articles were 
performed. Direct cost included cost of outpatient consultation, hospitalisation, 
medication, rehabilitation and the use of prescribed traditional Chinese medicine; 
whereas indirect cost included home care, transport, home support equipment, 
supplement use, and productivity loss. Results: Eleven articles (10 Mandarin and 1 
English) were selected and reviewed qualitatively. Approximately 80% of the articles 
reviewed received an average grade in terms of study quality. The average direct 
and indirect cost of managing PD in China reported ranged from RMB 7,000 (USD 
1,157) to RMB 15,000 (USD 2,479) per annum. The reported direct cost of managing 
PD ranged from RMB 1,600 (USD 265) to RMB 13,000 (USD 2,149); whereas the indirect 
cost reported ranged from RMB 2,970 (USD 491) to RMB 13,200 (USD 2,182). Seven 
out of 11 articles reported cost-effectiveness results. Three papers from the same 
authors had reported the main factors affecting the overall economic burden of 
PD. cOnclusiOns: Various combination therapy involving levodopa had higher 
direct costs but reduced indirect costs compared to levodopa monotherapy. In gen-
eral, the reported indirect cost is higher than direct cost of PD management in China.
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Objectives: To estimate the indirect burden of Alzheimer’s disease in 
US. MethOds: Applying the economic concept of the multiplier effect – the degree 
to which a change in aggregate demand may have a greater effect on national 
income – to the analysis of the indirect cost of Alzheimer’s disease can provide 
valuable insights to the societal burden of the disease. US demography forecasts and 
disease incidence rates were used to develop a Markov model for the Alzheimer’s 
patient population. Estimates for the indirect cost of Alzheimer’s were derived 
using key variables, such as hours spent on care per patient, severity of the illness, 
percentage in need of care by disease severity, and salaries. Results: The model 
predicted that the indirect burden of Alzheimer’s will increase by 85% from 2015-
2020, by 33% from 2020 to 2025 and by 17% from 2025-2030. The main cost drivers in 
the model are the unpaid work by carers and lost revenues due to mild Alzheimer’s 
patients having to leave the labor market. cOnclusiOns: By employing the mul-
tiplier model it was determined that the indirect costs attributed to Alzheimer’s 
disease have a significant impact on the total burden of the disease, due in part to 
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Objectives: Determine the cost-effectiveness of facial plastic surgery vs. 
OnabotulinumtoxinA for chronic migraine prophylaxis . MethOds: A Markov 
model comparing Onabotulinumtoxin A to a relatively new surgical treatment 
for chronic migraine headache was constructed from the payer perspective with 
a lifetime time horizon and one month cycle length. Efficacy and adverse event 
data were sourced from randomized, controlled trials of the two interventions 
relative to placebo or standard care, while costs came from mean wholesale pric-
ing of OnabotulinumtoxinA and proxy surgery costs. Utility scores were obtained 
for four Markov health states based on monthly headache frequency1) < 2, 2) 
2-6, 3) 7-15, and 4) > 15; and death. Subjects were assumed to start in a chronic 
migraine state. Costs and utility were discounted at 2%. Uncertainty was evaluated 
through one-way and probabilistic sensitivity analyses. All analysis was completed 
in Microsoft Excel 2013 (Redmond, WA). One-way sensitivity analysis was con-
ducted using TreePlan, SensIt 1.46 (San Francisco, CA). Results: Onabotulinum 
toxin A was significantly more expensive than surgery, while the two treatments 
had similar efficacy and surgery had fewer adverse effects. Surgical and post-
surgical care costs were $7,850 (95% CI $3,500; $20,000) compared to $25,000 (95% 
CI $15,000; 37,000); p< 0.001. Reduction in headache days was not significantly 
different between the interventions. A single surgical intervention for migraine 
has fewer side effects than quarterly OnabotulinumtoxinA treatments. Surgery 
dominates OnabotulinumtoxinA. cOnclusiOns: Surgery should be considered 
for chronic migraine. Third-party payers may be hesitant to pay for surgery given 
the larger upfront costs, while the benefits accrue over time – when the patient 
may be with a different payer.
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Objectives: Parkinson’s disease (PD) is associated with significant patient quality 
of life and economic burden. Motor symptoms include bradykinesia, rigidity, and 
tremor, and non-motor symptoms include psychosis, dementia, depression, anxi-
ety, and sleep disturbances. Many treatments focus on reducing motor symptoms. 
There is a lack of treatment options addressing non-motor symptoms even though 
non-motor symptoms such as psychosis and dementia have a direct impact on 
caregiver distress, nursing home placement and mortality. The objective of this 
study was to characterize published cost-effectiveness models, and to understand 
the extent to which they handle motor and nonmotor symptoms. MethOds: 
We conducted a targeted review of cost-effectiveness models for PD treatments, 
published in English since 2000. Information on model objective, structure, health 
states, population characteristics, time horizon, country and symptoms consid-
ered were extracted and summarized. Results: Fifteen cost-effectiveness models 
published since 2000 were identified and analyzed. Thirteen used a Markov model 
structure; one used a decision-tree; and one was a simple cost-minimization cal-
culation. Six of the Markov models basing their health states on the Hoehn and 
Yahr (HY) scale – a 5-stage scale that considers only motor symptoms. Time hori-
zons for the models ranged from one to 25 years. Ten countries were represented; 
three models focused on the US. All but two models (for cell replacement therapy 
and deep brain stimulation) evaluated drug treatments. All models evaluated 
treatments’ effects in terms of motor complications or motor fluctuations (on/
off periods). Only one model considered the effect of treatment on a non-motor 
symptom (dementia). cOnclusiOns: Although PD is associated with both motor 
and non-motor symptoms, there is a lack of cost-effectiveness models capturing 
treatment’s effects on non-motor symptoms. This may be due to a lack of standard 
assessment tools as well as limited treatment options for non-motor symptoms 
of PD. Further research is needed in this area.
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Objectives: To estimate the cost-effectiveness of delayed-release dimethyl fuma-
rate compared with glatiramer acetate and fingolimod in treatment of relapsing-
remitting multiple sclerosis (RRMS) in the US. MethOds: A cohort Markov model 
tracking patients through EDSS health states (cycle time 1 year) was developed 
in Excel to estimate the discounted (at 3 percent) cost and quality-adjusted life-
years (QALYs) with treatment with delayed-release dimethyl fumarate compared 
with glatiramer acetate or fingolimod in RRMS. Patients were assumed to stop 
DMT when their EDSS reached 7. Population characteristics matched those in 
the delayed-release dimethyl fumarate phase 3 clinical trials. Untreated transi-
tion rates between the EDSS health states and annualized relapse rates were 
estimated using data from the placebo arms of the phase 3 clinical trials. The 
impact of each DMT on disease progression and annualized relapse rates was 
estimated using a mixed-treatment comparison analysis of clinical trial data. 
Costs included drug acquisition, administration, monitoring and adverse event 
costs as well as other costs in each EDSS health state. Utility by EDSS health 
state and disutility associated with adverse events were also included. One-way 
sensitivity analyses were performed changing input parameter values and model 
assumptions. Results: Over a 10-year time horizon, compared with glatiramer 
acetate and fingolimod, delayed-release dimethyl fumarate increased QALYs by 
0.205 and 0.156 QALYs, respectively and was less costly by $8,094 and $30,522, 
case was 5 years. Outcomes included costs, Quality-adjusted Life Years (QALYs), 
incremental net monetary benefit (INMB) and incremental cost-effectiveness ratio 
(ICER). The societal willingness-to-pay (WTP) threshold was assumed to be $100,000 
per QALY and the costs were in 2012 US dollars. One-way sensitivity analyses and 
probabilistic sensitivity analyses were conducted to test the robustness of the model 
results. Results: The 5 years’ total costs per patient were estimated at $322,694, 
$339,457, $324,512 and $298,875 for IM IFN β -1a, fingolimod, teriflunomide, and 
dimethyl fumarate, respectively. The accumulated QALYs associated with each drug 
were 3.34, 3.69, 3.68 and 3.72, respectively. Dimethyl fumarate dominated all other 
therapies over the range of WTPs from $0 to $180,000. Compared with IM IFN β -1a, 
at the WTP of $100,000, INMBs were estimated at $18,510, $33,021, and $61,290 
for fingolimod, teriflunomide, and dimethyl fumarate, respectively. Compared 
with IM IFN β -1a, ICERs were $47,523 and $5,218 for fingolimod and teriflunomide, 
respectively, and the ICER of fingolimod versus teriflunomide was $3,451,748. One-
way sensitivity analysis demonstrated that model results were sensitive to the 
drug acquisition costs and time horizon, but in most scenarios, cost-effectiveness 
rankings remained stable. Probabilistic sensitivity analysis showed that for more 
than 90% of the simulations, dimethyl fumarate was the optimal therapy across all 
willingness-to-pay values. cOnclusiOns: Of the four disease-modifying drugs, 
dimethyl fumarate was a dominant therapy to manage RRMS. Apart from dimethyl 
fumarate, teriflunomide was the most cost effective therapy compared with IM IFN 
β -1a with an ICER of $5,218.
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Objectives: To determine cost-effectiveness of natalizumab compared with other 
disease-modifying therapies (DMT) for the treatment of relapsing-remitting mul-
tiple sclerosis (RRMS) in Russia. MethOds: Clinical and economical analysis was 
conducted using modeling (a decision tree model) and the “cost-effectiveness” 
method. A model was based on assumptions about the effectiveness of the com-
pared drugs derived from the Cochrane meta-analysis by Filippini G. et al. (2013). The 
information on the cost treatment information of RRMS was based on the Russian 
standards of care. Model inputs were drug acquisition costs (wholesale acquisi-
tion cost), costs of drug administration and monitoring, costs of treating relapses. 
The study time frame was 2 years. An annual discount rate of 5 % was applied 
to costs. Results: The overall 2-year cost of therapy per patient was 75,088 USD 
(2,493,682 RUB) for natalizumab (Tysabri), 47,187 USD (1,567,083 RUB) for intramus-
cular (IM) interferon beta-1a (Avonex), 47,075 USD (1,563,370 RUB) for subcutaneous 
(SC) interferon beta-1a (Rebif 44), 43,962 USD (1,459,976 RUB) for glatiramer acetate 
(Copaxone), and 39,826 USD (1,322,636 RUB) for interferon beta-1b (Betaferon). As a 
criterion of effectiveness a relative risk reduction of one or more relapses over 24 
months of treatment compared with placebo was chosen (42.8 % for natalizumab, 
21.6% for glatiramer acetate, 15.2% SC interferon beta-1a, 10.5% for interferon beta-
1b and 3.6% for IM interferon beta-1a). The cost per relapse avoided was lowest 
for natalizumab at 1,754 USD (58,264 RUB), followed by 2,035 USD (67,591 RUB) for 
glatiramer acetate, 3,097 USD (102,853 RUB) for subcutaneous (SC) interferon beta-
1a, 3,793 USD (125,965 RUB) for interferon beta-1b, and 13,108 USD (435,301 RUB) 
for intramuscular (IM) interferon beta-1a. cOnclusiOns: Natalizumab was the 
most cost-effective therapy for RRMS as measured by total cost of treatment per 
relapse avoided.
PND22
AN ecoNomIc ANAlysIs oF workPlAce screeNINg For obsTrucTIve sleeP 
APNeA
Kim R.D.1, Kapur V.K.2, Garrison L.2, Ramsey S.3
1Pharmaceutical Outcomes Research and Policy Program, Univerisity of Washington, Seattle, WA, 
USA, 2University of Washington, Seattle, WA, USA, 3Fred Hutchinson Cancer Research Center, 
University of Washington, Seattle, WA, USA
Objectives: Undiagnosed obstructive sleep apnea (“OSA”) is associated with 
decreased workplace performance and increased mortality. While the diagno-
sis and treatment of OSA in symptomatic individuals is highly cost-effective, 
it is unknown whether screening for OSA in the workplace can be cost-effec-
tive. MethOds: We modeled three strategies in a hypothetical cohort of 50 year 
old men: (1) No screening or intervention for OSA. (2) Refer all individuals for 
lab-based diagnostic polysomnography, followed by continuous positive airway 
pressure (“CPAP”) therapy in those diagnosed with OSA. (3) Screen individuals 
with a validated instrument (Berlin Questionnaire) delivered via email, followed 
by referral for polysomonography for those who screen positive and CPAP therapy 
in those diagnosed with OSA. Costs of managing the screening program, as well as 
various incentives to improve survey response, were also included in the model. 
Estimation of treatment benefits were taken from a previously published model 
(Pietzsch, et al). We took a societal perspective and a lifetime horizon. Results: 
The incremental cost-effectiveness ratio (“ICER”) for the Berlin Questionnaire 
strategy compared to no screening, was $41,749/QALY. By comparison, the ICER 
for the all-polysomnography strategy compared to no screening was $66,711/QALY. 
We then considered eight possible strategies to improve Berlin Questionnaire 
response rates and plotted them on a cost effectiveness frontier, and found that 
with maximum enhancement of survey response, the ICER decreased to $32,484/
QALY for the Berlin Questionnaire strategy. The cost of screening (not including 
diagnosis) without survey enhancement was $11/person; with maximal survey 
enhancement, it was $40/person. One-way sensitivity analysis found that the ICER 
was most sensitive to the size of the screening population, the prevalence of OSA, 
and the clinical benefit of OSA treatment. cOnclusiOns: Screening for OSA in 
the workplace using the Berlin Questionnaire can be cost-effective, particularly 
with use of survey response enhancement techniques.
